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TheObjectives: The effect of autologous skeletal myoblast transplantation has not been
rigorously studied in the setting of end-stage ischemic heart failure free of concom-
itant coronary revascularization. The aims of the present study were to determine
autologous skeletal myoblast survival and its effects on left ventricular function and
remodeling in sheep with dilated ischemic heart failure.
Methods: Ischemic heart failure (left ventricular ejection fraction, 30%  2%; left
ventricular end-systolic volume index, 82  9 mL/m2) was created in sheep (n 
11) with serial left circumflex coronary artery microembolizations. Instruments
were inserted for the long-term determination of left ventricular global and regional
dimensions, hemodynamics, and pressure-volume analysis after autologous skeletal
myoblast transplantation (approximately 3.0  108 myoblasts; heart failure plus
autologous skeletal myoblast group, n  5) or without (heart failure–control group,
n  6). Measurements were performed in conscious animals.
Results: Autologous skeletal myoblast–derived skeletal muscle was found in all
injected animals at 6 weeks. In ischemic heart failure, autologous skeletal myoblast
cardiomyoplasty failed to improve systolic (left ventricular ejection fraction, 29%
4%; dP/dTmax, 2863  152 mm Hg/s; end-systolic elastance, 1.6  0.22) or
diastolic (left ventricular end-diastolic pressure, 21  2 mm Hg; time constant of
relaxation (Tau), 34 4 ms; dP/dTmin,1880 68 mm Hg/s) function. There was,
however, attenuation in the left ventricular dilatation after autologous skeletal
myoblast transplantation (change in end-systolic volume index, 14%  4% vs 32%
 6%; P  .05). The effects of autologous skeletal myoblast–derived skeletal
muscle were exclusive to the left ventricular short-axis dimension and dependent on
autologous skeletal myoblast survival (R2  0.59, P  .006, n  11).
Conclusions: Autologous skeletal cardiomyoplasty was able to attenuate left ven-
tricular remodeling in sheep with end-stage ischemic heart failure.
Autologous skeletal myoblast (ASM) transplantation, or cardiomyoplasty,has been shown in multiple experimental studies to improve cardiac func-tion after myocardial infarction.1-7 Although the majority of studies have
been performed in small-animal models of myocardial infarction, there is evidence
of similar improvement in models involving larger animals8 and in the first patient
trials.9-12 The mechanism behind such positive functional changes remains poorly
understood given that developing and engrafted skeletal myoblasts are electrome-
chanically isolated from their host myocardium (as evidenced by the lack of
connexin-43, gap junctions, or both).4,8-10,12 Furthermore, clinical ASM cardiomy-
oplasty has been applied exclusively to patients with severe ischemic cardiomyop-
athy, and more importantly, it has always been performed as an adjunct to coronary
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device, or both.11 Because of these concomitant therapies,
the improvements in indices of myocardial perfusion, via-
bility, and function might be difficult to attribute to ASM
injection alone.
Additionally, growing experimental evidence suggests
that the number of ASM cells transplanted and the func-
tional-geometric effects are directly related.5,12 For exam-
ple, Tambara and associates,5 using fetal-derived ASM in
rats, demonstrated that both cardiac function and remodel-
ing were affected in a dose-dependent fashion. However,
these benefits have not been demonstrated in ischemic di-
lated heart failure (HF), where increased wall stresses and
altered myocardial mechanoenergetics could compromise
ASM survival, differentiation, and ultimately functional ef-
ficacy. Thus, the aims of the present study were to evaluate
LV remodeling and function after ASM transplantation in
an animal model of end-stage ischemic HF (LV ejection
fraction [LVEF] of 35% and LV end-systolic volume of
80 mL/m2). Furthermore the study also sought to evaluate
the survival, differentiation, and alignment of ASMs in-
jected in those same animals.
Materials and Methods
All experiments were approved by The Ohio State University
Institutional Laboratory Animal Care and Use Committee and
comply with published federal guidelines.
Ischemic HF Model
Experimental ischemic HF was created in sheep in the same way
as Sabbah and colleagues13 described in dogs, with minor modi-
fications. In brief, serial and selective left circumflex coronary
artery (LCxA) microembolizations (2.9  0.4 injections per ani-
mal) were performed by injecting polystyrene beads (70-110 m)
weekly until the LVEF was maintained at or less than 35% for 2
consecutive weeks.
Experimental Groups
The HF control group of sheep (baseline) was instrumented 2
weeks before LCxA microembolization and HF induction (HF
control, n  6). The transplanted group of sheep had LCxA
microembolization and HF induction before instrumentation and
injection with ASMs (HF plus ASM, n  5). Studies were per-
formed weekly for 6 weeks in awake and unsedated animals.
Instrumentation for Long-Term Monitoring
All sheep were instrumented through a left thoracotomy; an LV
solid-state electronic pressure transducer (4.0 or 4.5 mm, Konigs-
berg Instruments, Pasadena, Calif) was placed into the left ventri-
cle at its apex, and permanent, heparinized (1000 U/mL), fluid-
filled catheters (Tygon; Norton Performance Plastics, Akron,
Ohio) were inserted for monitoring of aortic, LV, and right ven-
tricular pressures. Six piezoelectric crystals (Sonometrics Inc, New
London, Ontario, Canada) were surgically placed in the LV endo-
cardium at the midpapillary level (short axis [SA]), at the LV base
and apex (long axis [LA]), and in the midmyocardium of the
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occluder (In Vivo Metrics, Healdsburg, Calif) was positioned
around the inferior vena cava. All catheters and cables were
tunneled to positions between the animals’ scapulas.
Hemodynamic Measurements and Pressure-Volume
Analysis
Aortic, right ventricular, and LV fluid-filled catheters were at-
tached to calibrated Statham pressure transducers (Model P23XL;
Biggo-Spectramed, Oxnard, Calif) and amplified (Gould, Valley,
Ohio). The electronic LV pressure gauge was calibrated by using
the LV fluid-filled catheter. Pressures waveforms were collected
(at 1 kHz) and analyzed by using a 16-channel data acquisition and
software system (IOX; EMKA Technologies, Falls Church, Va).
Sonometric signals were analyzed for waveform cardiac-cycle
dependent (end-diastolic and end-systolic) and independent (eg,
minimum, maximum, and mean) parameters. LV volume (in mil-
liliters) was calculated in real time by using SA and LA dimen-
sions and the following equation: (SA2LA/6)/1000.14 LV vol-
ume indices were calculated as follows: LV volume*Body surface
area (mL/m2). Inferior vena caval occlusions were performed for
the generation of pressure-volume (PV) relationships that were
analyzed offline with analysis software (IOX, EMKA
Technologies).
For information on skeletal muscle biopsy and ASM culture
and histology, see Appendix E1.
Statistical Analysis
Data are presented as means  standard error of the mean. The
differences between groups (treatments  HF plus ASM and
HF-control) over time for LV hemodynamic, geometric, and func-
tional data were studied with multifactorial (2-way) analysis of
variance with repeated measurements (factors  group and time).
If the F ratio exceeded a critical value (  .05), the post-hoc
Student-Newman-Keuls method was used to perform pairwise
comparisons (SigmaStat; Systat Software, Inc, Point Richmond,
Calif).
Individual PV relationships were computed by means of re-
gression analysis (IOX, EMKA Technologies). Additionally, the
equality of the PV relationships between the HF plus ASM and
HF-control groups was studied with multiple linear regression
considering both qualitative (group) and interaction terms (ie,
simultaneously testing the differences in slope and intersect of the
regression functions; Minitab R14; Minitab, Inc, State College,
Pa). Linear regression analyses were also performed to study the
relationship-interaction between indices of LV remodeling or
function and the estimated number of surviving ASM-derived
myocytes, including HF-controls as zero survival (Minitab R14,
Minitab, Inc).
The differences in the same control animals before HF (base-
line) and after HF (week 1) were studied by a paired Student t test
(SigmaStat, Systat Software, Inc) to validate the impaired physi-
ology of HF present in this model. However, because HF was
defined as both increased end-systolic volume index (ESVI) and
decreased LVEF (a null hypothesis consisting of 2 variables), the
Bonferroni method for multiple comparisons was used to correct
the level of confidence (  .025).
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Eleven sheep were studied for 6 weeks after establishment
of HF with (HF plus ASM, n  5) or without (HF-control,
n 6) ASM injection. Three of 8 sheep intended for the HF
plus ASM group died during the instrumentation procedure,
either before ASM injection (n 2) or within 72 hours after
injection, and were not included in the study. No sheep in
the HF-control group died early. Sheep were less active
after HF induction, but no differences in daily observations
were appreciated between groups.
Histology
The average number of injected myoblasts was 3.44  0.49
 108 cells, ranging from 1.53 to 4.3  108 cells. Myoblast
purity (92%  1.4%) and cell viability (93%  1.2%) were
assessed at the time of transport, and myoblast viability was
confirmed to be greater than 90% (by using trypan blue
exclusion) after shipment (4°C). ASM-derived skeletal
myofibers were found in all injected hearts, but the esti-
mated survival (see discussion) of injected myoblasts sur-
The Journal of Thoracic anviving at week 6 ranged from 158,000 cells (0.05% sur-
vival) to 36.4 million cells (10.7% survival).
Representative histologic sections with detailed descrip-
tions are found in Figure 1 and Figure E1. In general,
skeletal myocytes were seen aligned with other skeletal
muscle fibers, as well as aligned with remaining cardiac
myocytes (Figure 1, C-F; Figure E1, A and B). Engrafted
skeletal muscle fibers were characterized by staining to the
myosin heavy chain fast-twitch isoform (purple staining in
Figure 1, B, D, and F, and Figure E1, B). However, in no
section were ASM-derived myofibers seen stained for tro-
ponin I or connexin-43, despite close apposition to surviv-
ing cardiac myocytes (Figure E1, C and D, respectively).
Cardiac Hemodynamics
Hemodynamic data are summarized in Table 1. No animal
had improvement in dP/dTmax or LVEF after ASM injec-
Figure 1. Six weeks after ASM injection in
sheep with ischemic HF, composite
Trichrome (A) and skeletal muscle–specific
myosin heavy chain (B; MY-32, purple stain-
ing)–stained sections demonstrate extensive
patches of ASM-derived skeletal muscle fi-
bers engrafted in areas of myocardial scar. In
C and D, at higher magnification from panel A
(arrow), skeletal fibers were seen aligned
with each other and further organized into
myofibril bundles. ASM-derived skeletal mus-
cle aligned with remaining cardiac myocytes
(E, c) and with neighboring skeletal myofi-
bers, which was confirmed with staining for
MY-32 (F). Scale bars in panels B, D, and F are
2 mm, 0.5 mm, and 0.2 mm, respectively.tion. No linear relationship was found between the esti-
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P  .99) or dP/dTmax (R2  0.048, P  .543).
PV Analysis
Data for end-systolic pressure-volume relationship, preload
recruitable stroke work (PRSW), and LV work (PVA) from
HF-control and HF plus ASM sheep are summarized in
Table 1 and exemplified in Figure E2. As expected and
demonstrated by means of PV analysis, HF induction re-
sulted in significant decreases in the slope of PRSW (Mw)
and in the load-independent contractility index (Ees). No
significant differences between treatment groups were ob-
served at week 1, with both presenting comparable degrees
of dysfunction. Multiple linear regression analyses account-
ing for covariance between groups also demonstrated no
significant differences in slope (week 1, P  .614; week 6,
P  .519; power  1) or intercept (week 1, P  .945; week
6, P  .928; power  1) of the volume-adjusted PV
relationships. No linear relationship was found between the
estimated number of surviving cells and Ees (R2  0.088, P
 .436) or Mw (R2  0.018, P  .731).
There was an increase (rightward shift, P  .026) in the
V0 (x-intercept) of the Ees for the HF-control group from
week 1 to week 6 (Figure E2). The V0 tended (P  .20) to
decrease (leftward shift) over the 6 weeks in the HF plus
ASM animals, and a difference was noted (P  .014)
between the HF-control and HF plus ASM animals at week
TABLE 1. Cardiac hemodynamics after autologous skeleta
Baseline
(n  6)
HF-contro
week 1 (n 
Heart failure
ESVI, mL/m2 39  4 93 7
LVEF, % 48 2 30 2
HR, beats/min 109 4 126 7
LVSP, mm Hg 106 6 103 5
LVEDP, mm Hg 11 1 23 4
EDVI, mL/m2 75  7 135 9
dP/dTmax, mm Hg/s 3414 92 2428 3
dP/dTmin, mm Hg/s 2124 108 1582 1
Tau, ms 17 1 38 8
Pressure-volume analysis,
HFASM (n  4), HF-
control (n  5)
Ees 3.7  0.5 1.3 0
V0 18  3.9 39 7
Mw 97  7.4 66 1
Vw 50  9.5 88 4
Mean  standard error of the mean. HF, Heart failure; ASM, autologous sk
fraction; HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, le
derivative of pressure, Tau, time constant of relaxation (Weiss method); E
preload recruitable stroke work; Vw, x-intercept of preload recruitable str
1 within groups (1-way analysis of variance). ‡P  .05 between groups a6, supporting the hypothesis that ASM injection attenuated
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increased from week 1 to week 6 in the HF-control group (P
 .03) and remained different (P  .009) compared with
that seen in the HF plus ASM group at week 6 (Table 1 and
Figure E2).
Sonomicrometry and LV Segmental Function
LV regional and segmental data are presented in Table E1.
HF induction significantly (P  .05) increased the segmen-
tal length in the infarct region (SLpost) of HF-control ani-
mals. Over the course of the study (week 1 to week 6), no
significant differences were observed in SLpost for either
group of animals. LV segmental dyskinesia was present
after microembolization, and therefore both systolic bulging
and postsystolic shortening were evident in both groups
throughout the 6-week study.
Sonomicrometry and LV Dimensions
LVESVI and end-diastolic volume index were increased (P
 .05) from baseline in both groups at HF week 1; however,
there was no difference between groups at week 1 (Table 1).
In HF plus ASM animals LV dilatation was attenuated
compared with that seen in HF-control animals (P  .016)
by week 3 (change in ESVI: 5.3%  1.2% and 17.8% 
3.3%, respectively), and this difference progressed (P 
.006) out to week 6 (Figure 2). The difference in LV volume
resulted from a significant (P  .005) attenuation in SA
oblast transplantation
HF-control,
week 6 (n  6)
HFASM,
week 1 (n  5)
HFASM,
week 6 (n  5)
124  15†‡ 85 16 98  18‡
28 2 29  4 27  4
125 9 128 9 110  10†
102 7 103 2 106  4
26 3 21  2 22  3
170 15†‡ 118 16 131  21‡
1864 216† 2863 152 2166  174†
1423 147 1880 68 1713  84
39 4 34  4 44  3†
0.9 0.13 1.6 0.22 1.6  0.28
59 8.7†‡ 32 3.1 25 3.4‡
58 7.8† 67 5.9 57  8.0†
107 15†‡ 75 3.3‡ 71  2.9‡
l myoblast; ESVI, end-systolic volume index; LVEF, left ventricular ejection
ntricular end-diastolic pressure; EDVI, end-diastolic volume index; dP/dT,
d-systolic elastance; V0, x-intercept of end-systolic pressure volume; Mw,
ork. *P  .05 from baseline to HF-control (week 1). †P  .05 from week
ective times (2-way analysis of variance).l my
l,
6)
*
*
*
*
*
27*
73*
*
.11*
.8*
0.1*
.9*‡
eleta
ft ve
es, en
oke wdilatation alone (Figure 2). No difference (P  .05) was
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McConnell et al Surgery for Acquired Cardiovascular DiseaseFigure 2. LV dilatation (ESVI, top panel) and the increase in midpapillary short-axis length (SA, middle panel) were
attenuated after ASM injection (n  5, open bars) compared with that seen in HF-control animals (n  6, shaded
bars). LV long-axis length (LA, bottom panel) was not different between groups. All animals, including HF-control
animals, were used to evaluate the relationship of ASM-derived myocyte survival (log of surviving cells) compared
with that of LV remodeling (inset of each panel, n  11). Animals with the highest ASM-derived myocyte survival
demonstrated the greatest attenuation, particularly in LV short-axis dilatation. Correlative statistics are presented
for each relationship.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 4 1001.e5
Surgery for Acquired Cardiovascular Disease McConnell et alfound in LA dilatation between groups. Correlations of
ESVI, SA, and LA to estimated ASM survival are presented
in Figure 2.
Discussion
Few studies have examined the effect of ASM in hearts with
a preexisting and clinically significant degree of ischemic
dysfunction and remodeling (LVEF of35% with LVESVI
of 80 mL/m2). The goal of the present study was to
determine the therapeutic benefit of ASM cardiomyoplasty
in a clinically applicable model of ischemic dilated HF free
of the confounding factors associated with coronary revas-
cularization or other supportive therapies.
ASM-derived skeletal muscle was found in all injected
sheep at 6 weeks. As others have reported,4,7-12 no staining
for connexin-43 was found in ASM-derived skeletal mus-
cle. Transplanted ASM-derived skeletal myofibers aligned
with each other and with the remaining cardiac myofibers in
all sections (Figures 1 and E1). Such organized alignment of
the ASM-derived fibers suggests that these fibers remained
sensitive to stress-strain relationships found within the
myocardium.15-17
A major limitation with cell therapy in general is the
large percentage (up to 90%) of cells that are lost shortly
after injection.18,19 An explanation for this early loss might
be by means of lymphatic drainage, venous drainage, or
both, of the cells after direct intramyocardial injection.19
Other factors also likely contribute to the further loss of
cells that are retained within the myocardium-scar. Recent
investigations have shown that both the pretreatment20 and
transfection21 of ASM with vascular endothelial growth
factor improved cardiac function, presumably by enhancing
perfusion and nutrient delivery. Furthermore, strategies to
limit inflammation, apoptosis, or both, have also proved
beneficial to improving the efficacy after cellular cardiomy-
oplasty.22,23 However, we did not observe evidence for
inflammation at graft sites 6 weeks after injection (Figures
1 and E1). Even with relatively low myoblast cell survival
(Figure 1, animal with 1.1% cell survival), considerable
areas of scarred myocardium can be filled with viable myo-
fibers as a result of cell fusion and subsequent enlargement
of myofibers (approximately a 10-fold increase in ASM-
derived myofiber cross-sectional area per nucleus vs
myoblasts).
LV Function
Data evaluating cardiac performance after ASM injection in
Tables 1 and E1 suggest no improvement in any hemody-
namic parameter or index of cardiac contractility in sheep
with end-stage, dilated ischemic HF. The lack of a demon-
strable direct functional benefit observed in our study differs
from reports in other animal models using a single ischemic
insult (cryoinfarction,6 ligation,7 and coil embolization8)
1001.e6 The Journal of Thoracic and Cardiovascular Surgery ● Oand might be related to the chronic nature and severity of
LV dysfunction in our HF model (multiple microinfarctions
over several weeks). Thus in the sheep HF model the insult
might have more effectively exhausted remote myocardial
compensatory mechanisms preventing contribution from the
remote myocardium after ASM injection. This could ex-
plain that the discrepancy with results previously published
in sheep (Ghostine and colleagues8) after coronary occlu-
sion might be due to the worse LV structure and function in
our sheep.
Other possible explanations for the lack of observed
functional cardiac improvements include the extent of re-
modeling at the time of treatment, the methods used for cell
preparation, and technical flaws. We agree with the inter-
pretation offered by Jain and associates,7 in their ex vivo
preparation in rats, that modest functional improvements
observed after ASM injection were likely the result of
benefits to nonfunctional properties of the left ventricle (ie,
attenuated LV dilatation) rather than directly to LV contrac-
tion. In essence, less wall stress placed on remote cardiac
myocytes as a result of ASM-derived skeletal muscle pre-
venting further LV chamber dilatation would translate into
better remote myocardial function. Perhaps the earlier the
treatment, the sooner the benefits of ASM-derived skeletal
muscle could be realized on LV remodeling and the greater
the likelihood that the remote cardiomyocytes could ade-
quately compensate and contribute to global LV function.
With respect to differences in the cell preparation in our
study, the limited functional benefit of the ASM in our
report could have resulted from the greater myoblast purity
of our injectate, the method of cell expansion, cryopreser-
vation, rewarming, and/or the transportation of the ASM.
Unlike Pouzet and coworkers,12 who demonstrated in rats
stratified for LV function (LVEF) a significant correlation
with the number of cells injected to indices of LV function
and that those most severely impaired received the greatest
benefit, we were unable to demonstrate such a relationship
compared with the number of surviving ASM-derived myo-
cytes. Pouzet,12 Ghostine,8 and their colleagues present
myoblast purity of less than 50% at the time of injection and
showed improved systolic function, whereas we expanded a
more pure population of myoblasts (90% CD56) and
found none. Fibroblasts, as the major contaminant in these
cell preparations, on their own have not been reported to
enhance systolic function, as has been reported for myo-
blasts.24 However, we cannot rule out synergistic effects
between fibroblasts and myoblasts, which could account for
improved contractility in preparations that are 50% versus
90% pure.
Other obvious differences in the expansion and storage
of cells in our study include the cryopreservation and sub-
sequent thaw of cells before implantation, as well as ship-
ment at 4°C. Histologically, we could not document any
ctober 2005
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32), inflammation, ASM coalignment, and alignment with
remaining cardiomyocytes from surviving grafts in our
study compared with those reported by others.6-8,12 How-
ever, the overall effectiveness of cellular grafts is critically
linked to various aspects of cell expansion, preservation,
and mechanisms of tissue retention and therefore are legit-
imate targets to explore to improve the efficacy of cellular
cardiomyoplasty. Unfortunately, we did not directly study
or vary myoblast purities or, for that matter, any other
aspects of cell culture and preservation, leading us to cau-
tiously and intentionally avoid directly comparing the effi-
cacy of one cell type or mixture versus another given the
large difference in LV dysfunction and physiology in our
report compared with that in the work of others.8-12
In addition, we cannot rule out the possibility that we did
not adequately evaluate systolic function (Table 1), the time
of study might have been insufficient, or there were simply
an insufficient number of animals studied (the power of
these studies was only sufficient to observe a 50% improve-
ment in either LVEF or Ees). We believe, on the basis of our
studies, that with more severe LV dilation and dysfunction,
longer periods of time or perhaps larger doses of cells might
be required for functional changes to be observed.
LV Remodeling
The major observation of the present study was the attenu-
ation of LV dilatation after ASM transplantation (Figure 2).
Studies in both large and smaller animals have also shown
positive effects on LV dilatation after ASM injection.5-8,12
However, a novel finding of the current study was that
effects on LV dilatation were exclusive for the SA dimen-
sion. The mechanism that defines this preferential effect on
SA remodeling is not entirely clear. The idea that cellular
cardiomyoplasty might be directly affecting scar elasticity
and thereby limiting scar expansion is a possible explana-
tion for attenuated regional dilatation.25 Although we could
not find a measurable improvement in either postsystolic
shortening or systolic bulging after ASM injection, the
interplay of both in chronically ischemic myocardium has
not been well characterized.26
If ASM-derived skeletal myofibers can actively resist
forces (stretch) in line with their fibers, as demonstrated ex
vivo,3 and thereby limit LV dilatation, this might also
explain the observed attenuation to LV dilatation selectively
for the LV SA. For example, as the ventricle becomes
increasingly spherical after ischemic injury, the predomi-
nate cardiac fiber axis (eg, 60°) progressively reorients
horizontally to the SA (eg, 30°).25 We provide evidence that
ASM-derived skeletal myofibers were found aligned with
each other and with the remaining cardiac myocytes, and
therefore theoretically the engrafted ASM-derived myofiber
orientation would be more aligned with the LV SA. As
The Journal of Thoracic ansuggested by our data in a small number of animals, ASM-
derived myofibers might offer innate resistance to dilatory
forces on or along their fiber lengths, thereby selectively
preventing dilatation aligned with ASM engraftment along
the LV SA (Figure 2).
Study Limitations
The animal model used in the present study approximates
clinical ischemic HF in cause, degree of pathology, and
coronary anatomy.13,16,18 Microembolization does not fully
model the phenomenon of myocardial infarction leading to
ischemic HF in all patients, particularly in those patients
who have a single large infarct. Moreover, this model
greatly accelerates the disease progression typical for
chronic ischemic HF.16,27
Each animal underwent the same number and types of
procedures. Differences found between the groups in the
present study could have been a result of the timing of
instrumentation (and ASM injection). The fact that attenu-
ated dilatation was observed only in the SA dimension in
HF plus ASM animals, whereas LA dilatation was nearly
identical between the HF-control and HF plus ASM groups,
supports that differences observed between groups could
have been dependent on myoblast injection. We have at-
tempted to provide a best estimate of cell survival by using
standardized techniques to quantify the number of viable
ASM-derived myocytes at 6 weeks so that the relative
survival between animals could be compared; however,
significant sampling error can exist in the method used to
calculate cell survival.28 Therefore, values given for cell
survival should not be interpreted as absolute but only as a
standardized estimate.
Segmental function, regional function, or both, as mea-
sured by sonomicrometry, might have not adequately doc-
umented function in the exact area of ASM engraftment
because of the variability of ASM survival; however, myo-
blast injection was specifically targeted to and was found in
the immediate vicinity of the sonomicrometry crystals at 6
weeks. LV function in the awake animal preparation used in
this study, as evaluated through PV analyses, could not be
performed at extremely low ventricular volumes because of
autonomic activation and inevitable adverse hemodynamic
consequences. Therefore, the estimates Ees and Mw do not
include low-volume measurements. If the methods existed
in awake animals to permit an evaluation of function over a
wider range of preloads, as possible with an isolated heart
preparation,7 the possibility exists that a difference could
have been found in both the position and slope of these
relations.
Conclusions
The present study describes ASM transplantation in a clin-
ically applicable large-animal model of chronic ischemic
d Cardiovascular Surgery ● Volume 130, Number 4 1001.e7
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lack of direct functional effect on cardiac function in this
small group of animals, we were able to demonstrate a
significant attenuation in LV dilatation after ASM trans-
plantation. The attenuation in LV dilatation was exclusive
to the SA and correlated with an estimate of surviving
ASM-derived myocytes. These observations suggest that
ASM affects LV remodeling through a mechanism indepen-
dent of cell-to-cell communication, direct functional im-
provements, or both, but that ASM engraftment and align-
ment might play a role in such a mechanism.
We thank Angela Phillips for her expert technical assistance in
completing these studies and Kristie Wetzel for histologic assis-
tance.
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Discussion
Dr Robert C. Robbins (Stanford, Calif). Myocardial restoration
has received a lot of recent hype. It has led the US Food and Drug
Administration to step in and stop the craziness and stop limiting
all these clinical trials. You now are required to get an investiga-
tional new drug protocol to do any trials with cell therapy. This is
a very important study. First, it was done in large animals. Almost
all the data that went from the laboratory to clinical trials were
obtained in rodents. That makes this is a very important study. As
indicated in the conclusion, it is important in that there was not
magical improvement in restoration in function. It just simply
prevented dilatation of the heart, sort of a biologic acorn device.
Because cell survival was correlated with function, what factors
do you attribute to the low cell survival? Certain things that you
did not comment on, such as ischemia, apoptosis, and inflamma-
tion, could be factors, but one of the things that I was particularly
interested in is 150 to 430 million cells. How was there this much
variety in the number of cells? Why in factors related to survival?
Dr McConnell. To the first factor—and that is the Achilles
heel of this therapy in general—how do we get more cells to
survive this transplantation process? I think in most circumstances
about 95% of the cells are lost within the first 24 hours, and at least
with the direct surgical technique, most of those are thought to be
lost because of the process of venous and lymphatic clearance
during the injection and then leaking back out of the myocardium
after the injection because again you are not making a new space.
You are simply filling a potential space, and as the remaining
myocardium and scar contracts, those cells are exuded and phys-
ctober 2005
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direct mechanical compromise to those cells. Then there are all of
those things that you brought up, such as apoptosis and inflam-
mation, regulating survival that in key instances are likely events.
We did not study that directly with these animals but have studies
ongoing that are looking at those various aspects. I think cell
retention is probably the biggest single hurdle that we need to get
over in the therapy.
In this particular study we had one animal that received 1.5
million cells versus the other animals that had up to 400 million
cells. There was a portion of one sample that was not available to
us. That is why there is a lower number in one instance. As far as
the animals that received the higher number, one can—at least in
these adult healthy sheep—get these cells to culture up to about a
billion within 3 weeks. Now in patients, they are older, with other
disease processes, and their myoblasts probably do not have the
ability to augment or culture up to that level as quickly.
Dr Robbins. I have one more question. Was there any mitral
regurgitation (MR) in these animals? You did not comment on that
in your article. And at the end of 6 weeks, even though there was
no difference in LV function and you cannot really do MVO2, but
just your observation, could you tell the difference in the animals?
Did one group have HF and the other not, or were they all about
the same?
Dr McConnell. Qualitatively, I could not tell any difference in
the animals. As far as MR, all of these animals had some degree of
The Journal of Thoracic anMR. We did not systematically study that phenomenon in these
animals, but you can tell from our PV data that when you use
sonomicrometry, you are obviously instrumenting the ventricle,
and therefore you are looking at the volume work that the ventri-
cles are performing. We actually had an enlargement in the stroke
volume simply because a portion of that was going toward MR.
Dr Edward Verrier (Seattle, Wash). Dr McConnell, are these
the wrong cells? Do we need a more elementary stem cell, or do
we need a different environment with different angiogenic factors
or growth factors in addition to just the myoblasts for it to work?
Dr McConnell. I would not say just at face value that it did not
work. One advantage of these cells is that they already are a fair
distance down their lineage toward a myocyte. With more rudi-
mentary cells or pluripotential cells, it is more and more difficult
to direct their lineage toward cardiomyogenesis per se. That would
be the ideal. Now obviously in the world of stem cells, the
paracrine effects of these stem cells, particularly in their ability to
effect apoptosis and other processes that might indirectly improve
cardiac function, is important; myoblasts might have less effect in
that regard. However, there are several camps that are developing
this idea, Dr Menashé in Europe has recently discussed this idea of
a paracrine effect these myoblasts are having, mainly through
hepatocyte growth factor and other mediators. But again, that is to
explain the phenomenon that these cells have increased cardiac
function that we, in this large animal model, were unable to
demonstrate.
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Skeletal Muscle Biopsy, ASM Culture, and
Histology
Skeletal muscle biopsy specimens (1-3 g) were harvested from the
left forelimbs of sheep at the time of the first microembolization in
the HF plus ASM group. The forelimb muscle was exposed, and
the biopsy specimen was taken by using sharp dissection, avoiding
electrocautery, and placed into a tube containing biopsy transport
media and shipped to GenVec, Inc (Charlestown, Mass) for ASM
preparation and culture similar to that described by Jain and
associates (2000).
All cells were expanded for 11 to 12 doublings and cryopre-
served before transplantation. The myoblasts were thawed, formu-
lated in transplantation media, and shipped for direct myocardial
injection. Myoblast purity was measured by means of reactivity
with anti-NCAM mAb (CD56-PE, Clone MY-31; BD Biosciences,
San Diego, Calif) and by the ability to fuse into multinucleated
myotubes. Cell viability was determined by means of trypan blue
exclusion. Myoblasts were loaded into tuberculin syringes (ap-
proximately 1.0  108 cells/mL) and shipped at 4°C. At the time
of transplantation, cells were allowed to warm slowly to room
temperature, resuspended by means of gentle agitation, and in-
jected without further manipulation. ASMs were injected at mul-
tiple sites in the infarcted myocardium in proximity to segmental
sonomicrometry crystals. To avoid inadvertent intravascular or
intraventricular injection of cells, the injection needle was passed
into the midmyocardium equidistant from the epicardial and en-
docardial surfaces over a 3- to 4-cm distance, negative pressure
was applied to the syringe, and if no blood was returned, the cells
were injected as the needle was slowly withdrawn. Slight pressure
was applied over the needle exit site for several seconds after
injection to limit cell efflux from the needle track.
After 6 weeks of study, each animal was killed, and the heart
was removed and perfused with 10% buffered formalin. Tissue
blocks were made from embolized myocardium receiving ASM
injection. Hematoxylin and eosin and Trichrome stains were per-
formed with standard methods.
Immunohistochemistry
Deparaffinized sections were stained immunohistochemically with
an anti-myosin heavy chain antibody that does not react with
cardiac muscle, alkaline phosphatase–conjugated MY-32 mAb
1001.e10 The Journal of Thoracic and Cardiovascular Surgery ●(Sigma, St Louis, Mo), to confirm the phenotype of the mature
grafts. Sections were developed with BCIP-NBT (Zymed Lab Inc,
San Francisco, Calif) and counterstained with nuclear red. Addi-
tionally, stains for connexin-43 antibody (Chemicon, Temecula,
Calif) and cardiac specific troponin I (Chemicon) were performed.
Estimation of Myoblast Survival
The heart was cut into blocks approximately 2.5 cm  2.5 cm 
3 mm in dimension and processed in paraffin. In some cases the
whole block was sectioned (5-m thickness), and in other cases
only a portion of the tissue was sectioned. For performing quan-
titative cell counts, tissue sections were then immunostained for
skeletal specific myosin heavy chain (MY-32). Cell viability at 6
weeks was assumed on the basis of the initiation of myosin heavy
chain expression (Havenith, 1990), cytoarchitectural organization
consistent with skeletal myocytes, and the presence of normal-
appearing nuclei located peripherally. By using representative
tissue sections and computer-assisted imaging analysis, the areas
of engraftment were calculated and converted to the number of
engrafted nuclei according to a separate count of nuclei density
performed on Trichrome-stained sections. The total number of
surviving myoblast nuclei in each tissue block was estimated by
using the following equation:
Sum of graft area in section  Density of nuclei per graft area 
No. of sections per block* Abercrombie connection
(Abercrombie, 1946).
*Estimated number of sections per block according to approximate
block thickness of 3 mm and section thickness of 5 m.
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McConnell et al Surgery for Acquired Cardiovascular DiseaseFigure E1. Viable muscle within an area of myocardial fibrosis and scar is seen with Trichrome staining (A).
Staining with MY-32 (B) confirmed that ASM-derived skeletal muscle engrafted in close proximity and aligned with
remaining cardiac myocytes (c) did not selectively stain for troponin I (C). At higher magnification from the same
area (C, arrow), ASM-derived skeletal myocytes do not stain for connexin-43 (D), despite very close apposition to
remaining cardiac myocytes (c). Scale bars in panels A and D are 0.2 mm and 0.1 mm, respectively.
TABLE E1. Left ventricular regional and segmental function after autologous skeletal myoblast transplantation
Baseline
(n  6)
HF-control,
week 1
(n  6)
HF-control,
week 6
(n  6)
HFASM,
week 1
(n  5)
HFASM,
week 6
(n  5)
SAES (mm) 37.9 2.5 51.8 2.9* 57.6 3.6† 51.5 4.9 53.4  4.9
SA (% short) 22.3 1.2 14.3 2.3* 13.3 1.7 15.2 0.8 13.0  1.4
LAES (mm) 73.2 3.8 83.7 5.2* 90.2 4.6† 80.4 4.1 85.5  4.9
LA (% short) 11.8 0.9 9.8 1.1* 8.5 1.6 8.5 0.9 8.1  1.9
SLpost (mm) 13.7 3.4 17 4.7* 18.9 5.6 12  1.3 12.1  1.3
SLpost (% short) 7.8  1.6 1.6  1.1* 2.1  1.8 1.8  2.2 2.4  1.8
SB (mm) 0.04 0.03 0.42 0.10* 0.53 0.16 0.40 0.14 0.43  0.18
PSS (mm) 0.06 0.04 0.47 0.13* 0.61 0.2 0.45 0.13 0.57  0.12
Mean  standard error of the mean. HF, Heart failure; ASM, autologous skeletal myoblast; SA, left ventricular short axis; ES, end systolic; % short,
percentage of systolic shortening; LA, left ventricular long axis; SLpost, posterior left ventricular segment (microembolized); SB, systolic bulging; PSS,
postsystolic shortening. *P  .05 from baseline. †P  .05 from week 1 within groups.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 4 1001.e11
Surgery for Acquired Cardiovascular Disease McConnell et alFigure E2. LV volume (LVV) and LV pressure (LVP) tracings from a single sheep before and after microembolization (top
and middle panels); highlight changes in the ESPVR (middle) and the PRSW (bottom, squares) with or without ASM
transplantation (bottom panel, circles) after microembolization. Although ASM transplantation did not improve cardiac
function (slope) after week 1 (open symbols), transplantation did prevent a rightward shift in the PRSW seen in the HF
control animal at week 6 (filled symbols).1001.e12 The Journal of Thoracic and Cardiovascular Surgery ● October 2005
